Voyager Therapeutics, Inc. (VYGR) shareholders
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander Joint filing with Millennium Management LLC (7.40%), Millennium Group Management LLC (7.40%) and 1 more | 4,442,951 | 7.40% | 13G (passive) amendment | Jun 30, 2026 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (6.80%), EcoR1 Capital Fund Qualified, L.P. (6.40%) | 4,002,847 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 3,525,532 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (5.87%) | 3,500,000 | 5.87% | 13G (passive) amendment | Mar 31, 2026 |
| Steven Boyd Joint filing with Armistice Capital, LLC (5.58%) | 3,436,000 | 5.58% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VYGR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,172,063 | 8.39% | $18.10M | −396,318 | 0.00% |
| Millennium Management LLC | 4,442,951 | 7.21% | $15.55M | +1,014,380 | 0.01% |
| Armistice Capital, LLC | 3,436,000 | 5.58% | $12.03M | −64,000 | 0.15% |
| Vestal Point Capital, LP | 2,625,000 | 4.26% | $9.19M | −377,936 | 0.21% |
| Vanguard Capital Management LLC | 2,345,674 | 3.81% | $8.21M | +62,421 | 0.00% |
| Geode Capital Management, LLC | 1,330,492 | 2.16% | $4.66M | +280,514 | 0.00% |
| Opaleye Management Inc. | 1,185,000 | 1.92% | $4.15M | +35,000 | 0.38% |
| State Street Corp | 1,076,422 | 1.75% | $3.77M | +128,196 | 0.00% |
| Two Sigma Investments, LP | 948,517 | 1.54% | $3.32M | +332,857 | 0.00% |
| Dimensional Fund Advisors LP | 838,184 | 1.36% | $2.93M | −37,384 | 0.00% |
| Vanguard Portfolio Management LLC | 810,091 | 1.31% | $2.84M | +84,322 | 0.00% |
| Citadel Advisors LLC | 784,067 | 1.27% | $2.74M | +419,403 | 0.00% |
| Morgan Stanley | 697,334 | 1.13% | $2.44M | +15,623 | 0.00% |
| Erste Asset Management GmbH | 638,900 | 1.04% | $2.29M | −456,241 | 0.02% |
| Renaissance Technologies LLC | 495,236 | 0.80% | $1.73M | −82,788 | 0.00% |
| Acadian Asset Management LLC | 428,670 | 0.70% | $1.50M | +179,799 | 0.00% |
| Sphera Funds Management Ltd. | 427,554 | 0.69% | $1.50M | −42,207 | 0.20% |
| Diadema Partners LP | 413,642 | 0.67% | $1.45M | −10,000 | 0.18% |
| Northern Trust Corp | 411,803 | 0.67% | $1.44M | +26,960 | 0.00% |
| Aqr Capital Management LLC | 356,109 | 0.58% | $1.25M | +123,428 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 136 | 35M | 56.9% | 19 / 58 | 34 / 16 | 4M | 3M |
| Q1 2026 | 135 | 34M | 54.4% | 28 / 46 | 36 / 17 | 10M | 7M |
| Q4 2025 | 125 | 34M | 54.8% | 19 / 30 | 46 / 8 | 6M | 2M |
| Q3 2025 | 117 | 30M | 49.4% | 23 / 33 | 38 / 18 | 3M | 6M |
| Q2 2025 | 112 | 33M | 54.3% | 14 / 33 | 36 / 18 | 3M | 5M |
| Q1 2025 | 116 | 35M | 56.4% | 13 / 35 | 41 / 27 | 2M | 2M |
| Q4 2024 | 132 | 35M | 56.2% | 25 / 44 | 37 / 18 | 3M | 3M |
| Q3 2024 | 128 | 35M | 57.5% | 20 / 38 | 36 / 18 | 7M | 5M |
| Q2 2024 | 127 | 38M | 62.3% | 23 / 41 | 42 / 28 | 5M | 3M |
| Q1 2024 | 132 | 36M | 59.2% | 33 / 57 | 29 / 7 | 10M | 1M |
| Q4 2023 | 107 | 28M | 44.8% | 20 / 33 | 30 / 23 | 3M | 2M |
| Q3 2023 | 110 | 27M | 44.2% | 21 / 35 | 33 / 17 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
127 funds held VYGR in Q2 2026, 61% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VYGR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,671,885 | 2.71% | $5.85M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,376,036 | 2.23% | $4.82M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 613,128 | 1.00% | $2.15M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 570,437 | 0.93% | $1.73M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 489,996 | 0.80% | $1.71M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 457,063 | 0.74% | $1.38M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 348,405 | 0.57% | $1.22M | 0.01% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 240,078 | 0.39% | $929.10K | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 225,281 | 0.37% | $871.84K | 0.02% | May 29, 2026 |
| U.S. Small Cap Portfolio | 220,820 | 0.36% | $669.08K | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 220,367 | 0.36% | $852.82K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 176,641 | 0.29% | $618.24K | 0.04% | Jun 30, 2026 |
| Bridge Builder Tax Managed Small/Mid Cap Fund | 157,086 | 0.25% | $549.80K | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 138,411 | 0.22% | $484.44K | 0.01% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 128,451 | 0.21% | $389.21K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alfred Sandrock | President and CEO, Director | 472,549 | 0.77% | Apr 3, 2026 |
| Robin Swartz | President | 267,988 | 0.43% | Nov 3, 2026 |
| Todd Alfred Carter | Chief Scientific Officer | 178,718 | 0.29% | Nov 3, 2026 |
| Amy Quinlan | Principal Accounting Officer | 36,749 | 0.06% | May 18, 2026 |
| Gregory L. Shiferman | SVP and General Counsel | 50,000 | 0.08% | Apr 3, 2026 |
| Nathan D. Jorgensen | Chief Financial Officer | 151,416 | 0.25% | Feb 26, 2026 |
| Toby Ferguson | Chief Medical Officer | 183,914 | 0.30% | Feb 10, 2026 |
| Sandell Jacquelyn Fahey | Chief Legal Officer | 123,143 | 0.20% | Feb 24, 2025 |
| Catherine J. Mackey | Director | – | – | Jun 11, 2026 |
| Nancy Vitale | Director | – | – | Jun 11, 2026 |
| James A. Geraghty | Director | 76,588 | 0.12% | Jun 11, 2026 |
| George A. Scangos | Director | – | – | Jun 11, 2026 |
| Michael J. Higgins | Director | 31,314 | 0.05% | Jun 11, 2026 |
| Steven Hyman | Director | – | – | Jun 11, 2026 |
| Glenn Pierce | Director | 21,788 | 0.04% | Jun 11, 2026 |
| Grace Colon | Director | – | – | Jun 11, 2026 |
| Jude Onyia | Director | 2,910 | 0.00% | Jun 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Todd Alfred Carter Chief Scientific Officer | Nov 1, 2026 | Award | +33,000 | – | – | 178,718 |
| Robin Swartz President | Nov 1, 2026 | Award | +68,250 | – | – | 267,988 |
| Alfred Sandrock President and CEO, Director | Apr 2, 2026 | Sale(10b5-1 plan) | −11,511 | $3.87 | $44.55K | 472,549 |
| Gregory L. Shiferman SVP and General Counsel | Apr 1, 2026 | Award | +50,000 | – | – | 50,000 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,668 | $3.77 | $17.60K | 151,416 |
| Robin Swartz COO & CBO | Feb 24, 2026 | Sale(10b5-1 plan) | −6,458 | $3.77 | $24.35K | 199,738 |
| Todd Alfred Carter Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,174 | $3.76 | $15.69K | 145,718 |
| Alfred Sandrock President and CEO, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −14,197 | $3.79 | $53.81K | 484,060 |
| Todd Alfred Carter Chief Scientific Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −3,301 | $3.44 | $11.36K | 149,892 |
| Alfred Sandrock President and CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −11,732 | $3.41 | $40.01K | 498,257 |
| Robin Swartz COO & CBO | Feb 18, 2026 | Sale(10b5-1 plan) | −3,882 | $3.44 | $13.35K | 206,196 |
| Alfred Sandrock President and CEO, Director | Feb 10, 2026 | Sale | −12,192 | $3.78 | $46.09K | 509,989 |
| Robin Swartz COO & CBO | Feb 10, 2026 | Sale | −4,569 | $3.85 | $17.59K | 210,078 |
| Todd Alfred Carter Chief Scientific Officer | Feb 10, 2026 | Sale | −3,525 | $3.85 | $13.57K | 153,193 |
| Robin Swartz COO & CBO | Feb 6, 2026 | Award | +45,000 | – | – | 214,647 |
| Alfred Sandrock President and CEO, Director | Feb 6, 2026 | Award | +86,250 | – | – | 522,181 |
| Toby Ferguson Chief Medical Officer | Feb 6, 2026 | Award | +45,000 | – | – | 183,914 |
| Todd Alfred Carter Chief Scientific Officer | Feb 6, 2026 | Award | +33,000 | – | – | 156,718 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 6, 2026 | Award | +32,250 | – | – | 156,084 |
| Nathan D. Jorgensen Chief Financial Officer | Oct 3, 2025 | Sale(10b5-1 plan) | −7,666 | $4.78 | $36.64K | 123,834 |
| Toby Ferguson Chief Medical Officer | Aug 18, 2025 | Sale | −19,000 | $3.73 | $70.87K | 138,914 |
| Alfred Sandrock President and CEO, Director | Apr 2, 2025 | Sale | −10,885 | $3.43 | $37.34K | 430,931 |
| Toby Ferguson Chief Medical Officer | Apr 2, 2025 | Sale | −10,086 | $3.43 | $34.59K | 157,914 |
| Nathan D. Jorgensen Chief Financial Officer | Feb 21, 2025 | Award | +51,500 | – | – | 131,500 |
| Toby Ferguson Chief Medical Officer | Feb 21, 2025 | Award | +63,000 | – | – | 168,000 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 21, 2025 | Award | +41,500 | – | – | 123,143 |
| Alfred Sandrock President and CEO, Director | Feb 21, 2025 | Award | +145,000 | – | – | 441,816 |
| Robin Swartz COO & CBO | Feb 21, 2025 | Award | +71,250 | – | – | 169,647 |
| Todd Alfred Carter Chief Scientific Officer | Feb 21, 2025 | Award | +46,000 | – | – | 123,718 |
| Alfred Sandrock President and CEO, Director | Feb 20, 2025 | Sale | −11,702 | $4.24 | $49.62K | 296,816 |
| Robin Swartz COO & CBO | Feb 20, 2025 | Sale | −3,894 | $4.25 | $16.55K | 98,397 |
| Todd Alfred Carter Chief Scientific Officer | Feb 20, 2025 | Sale | −3,305 | $4.26 | $14.08K | 77,718 |
| Alfred Sandrock President & CEO | Feb 11, 2025 | Sale | −16,644 | $4.45 | $74.07K | 308,518 |
| Todd Alfred Carter Chief Scientific Officer | Feb 11, 2025 | Sale | −5,413 | $4.45 | $24.09K | 81,023 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 11, 2025 | Sale | −4,358 | $4.45 | $19.39K | 81,643 |
| Robin Swartz COO & CBO | Feb 11, 2025 | Sale | −6,950 | $4.45 | $30.93K | 102,291 |
| Robin Swartz COO & CBO | Jan 14, 2025 | Sale | −3,087 | $5.09 | $15.71K | 109,241 |
| Todd Alfred Carter Chief Scientific Officer | Jan 14, 2025 | Sale | −1,191 | $5.13 | $6.11K | 86,436 |
| Robin Swartz COO&CBO | Dec 23, 2024 | Sale | −6,500 | $5.65 | $36.73K | 112,328 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Oct 2, 2024 | Sale | −5,999 | $5.82 | $34.91K | 86,001 |
| Nathan D. Jorgensen Chief Financial Officer | Oct 1, 2024 | Award | +80,000 | – | – | 80,000 |
| Alfred Sandrock President and CEO, Director | Apr 2, 2024 | Sale | −12,115 | $9.86 | $119.45K | 322,839 |
| Robin Swartz Chief Operating Officer | Apr 2, 2024 | Sale | −1,357 | $9.88 | $13.41K | 117,004 |
| Toby Ferguson Chief Medical Officer | Apr 1, 2024 | Award | +105,000 | – | – | 105,000 |
| Peter P. Pfreundschuh Chief Financial Officer | Feb 21, 2024 | Sale | −3,764 | $7.46 | $28.08K | 175,669 |
| Todd Alfred Carter Chief Scientific Officer | Feb 21, 2024 | Sale | −3,365 | $7.47 | $25.14K | 87,627 |
| Robin Swartz Chief Operating Officer | Feb 21, 2024 | Sale | −3,966 | $7.45 | $29.55K | 118,361 |
| Alfred Sandrock President and CEO, Director | Feb 21, 2024 | Sale | −13,033 | $7.46 | $97.23K | 334,954 |
| Todd Alfred Carter Chief Scientific Officer | Feb 20, 2024 | Sale | −602 | $7.68 | $4.62K | 90,992 |
| Peter P. Pfreundschuh Chief Financial Officer | Feb 9, 2024 | Award | +30,000 | – | – | 179,433 |
| Alfred Sandrock President and CEO, Director | Feb 9, 2024 | Award | +130,000 | – | – | 347,987 |
| Todd Alfred Carter Chief Scientific Officer | Feb 9, 2024 | Award | +38,500 | – | – | 91,594 |
| Robin Swartz Chief Operating Officer | Feb 9, 2024 | Award | +50,000 | – | – | 122,327 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Feb 9, 2024 | Award | +31,000 | – | – | 92,000 |
| Robin Swartz Chief Operating Officer | Jan 17, 2024 | Sale | −2,543 | $7.15 | $18.18K | 72,327 |
| Todd Alfred Carter Chief Scientific Officer | Jan 17, 2024 | Sale | −1,266 | $7.18 | $9.09K | 53,094 |
| Peter P. Pfreundschuh Chief Financial Officer | Oct 3, 2023 | Sale | −13,567 | $6.99 | $94.83K | 149,433 |
| Sandell Jacquelyn Fahey Chief Legal Officer | Oct 1, 2023 | Award | +61,000 | – | – | 61,000 |
| Todd Alfred Carter Chief Scientific Officer | Sep 15, 2023 | Option exercise | +5,000 | $2.85 | $14.25K | 64,860 |
| Todd Alfred Carter Chief Scientific Officer | Sep 15, 2023 | Sale(10b5-1 plan) | −10,500 | $8.16 | $85.68K | 54,360 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Voyager Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,770 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nathan D. Jorgensen Former Officer | May 15, 2026 | 9,406 | $39.88K | May 15, 2026 | Option Granted - 02/06/2026 |
| Nathan D. Jorgensen Former Officer | May 15, 2026 | 25,000 | $96.94K | May 15, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Apr 2, 2026 | 11,511 | $44.60K | Apr 2, 2026 | Restricted Stock Vesting |
| Nathan D. Jorgensen Officer | Feb 24, 2026 | 4,668 | $17.59K | Feb 24, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 24, 2026 | 14,197 | $53.85K | Feb 24, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 24, 2026 | 6,458 | $24.34K | Feb 24, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 24, 2026 | 4,174 | $15.71K | Feb 24, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 18, 2026 | 3,882 | $13.35K | Feb 18, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 18, 2026 | 3,301 | $11.35K | Feb 18, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 18, 2026 | 11,732 | $40.04K | Feb 18, 2026 | Restricted Stock Vesting |
| Robin Swartz Officer | Feb 10, 2026 | 4,569 | $17.60K | Feb 10, 2026 | Restricted Stock Vesting |
| Todd Alfred Carter Officer | Feb 10, 2026 | 3,525 | $13.55K | Feb 10, 2026 | Restricted Stock Vesting |
| Alfred Sandrock Officer, Director | Feb 10, 2026 | 12,192 | $46.09K | Feb 10, 2026 | Restricted Stock Vesting |
| Nathan D. Jorgensen Officer | Oct 3, 2025 | 7,666 | $36.63K | Oct 3, 2025 | Restricted Stock Vesting |
| Sandell Jacquelyn Fahey Officer | Oct 3, 2025 | 5,843 | $27.94K | Oct 3, 2025 | Restricted Stock Vesting |
See a number that looks wrong?